JPMorgan Chase & Co. Boosts Holdings in Atyr PHARMA INC (NASDAQ:ATYR)

JPMorgan Chase & Co. raised its holdings in shares of Atyr PHARMA INC (NASDAQ:ATYR) by 52.0% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 31,440 shares of the company’s stock after acquiring an additional 10,754 shares during the quarter. JPMorgan Chase & Co.’s holdings in Atyr PHARMA were worth $55,000 as of its most recent filing with the Securities and Exchange Commission.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on ATYR shares. HC Wainwright reissued a “buy” rating and issued a $35.00 target price on shares of Atyr PHARMA in a research report on Tuesday, December 10th. Cantor Fitzgerald started coverage on shares of Atyr PHARMA in a research report on Monday, January 6th. They set an “overweight” rating on the stock. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $19.25.

Atyr PHARMA Trading Down 7.5 %

Shares of ATYR stock opened at $3.57 on Tuesday. The stock has a market cap of $299.67 million, a price-to-earnings ratio of -3.80 and a beta of 1.10. The firm’s 50 day moving average price is $3.48 and its two-hundred day moving average price is $2.70. Atyr PHARMA INC has a fifty-two week low of $1.42 and a fifty-two week high of $4.22. The company has a quick ratio of 5.41, a current ratio of 5.41 and a debt-to-equity ratio of 0.02.

Atyr PHARMA (NASDAQ:ATYR) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.01). On average, analysts anticipate that Atyr PHARMA INC will post -0.91 EPS for the current year.

Atyr PHARMA Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.